Medical Account Specialists - Hematology

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Regeneron and Sanofi expand collaboration to develop long-acting immunology antibodies. Thursday, October 01, 2026 Regeneron Pharmaceuticals and Sanofi have expanded their long-standing antibody collaboration to develop and commercialise a new group of long-acting immunology treatments. Dupixent is a fully human monoclonal antibody that blocks signalling through the IL-4 and IL-13 pathways. It was developed using Regeneron's VelocImmune technology and is not an immunosuppressant. The agreement builds on more than two decades of work between the companies and their development of Dupixent (dupilumab), a widely used treatment for diseases linked to type 2 inflammation. Under the expanded agreement, the companies will jointly develop and commercialise four long-acting antibodies discovered by Regeneron. The candidates target interleukin-13 (IL-13), IL-4 and IL-4 pathways, including an IL-4xIL-13 bispecific antibody and an antibody targeting the IL-4 receptor alpha (IL-4Rα). REGN20423, an IL-13 antibody, is currently being evaluated in a Phase 1 clinical trial for atopic dermatitis. The other three antibody programmes are expected to enter clinical studies in 2027. Regeneron will also have the option to add Sanofi's investigational lunsekimig to the collaboration after completion of its Phase 3 trials in chronic obstructive pulmonary disease. Lunsekimig is a bispecific Nanobody therapy designed to target thymic stromal lymphopoietin (TSLP) and IL-13. As part of the agreement, Sanofi will pay Regeneron $1 billion upfront. Regeneron could receive up to a further $7 billion through development, regulatory and commercial milestones. The companies will share development and commercialisation costs for the new programmes and divide future profits equally worldwide. Regeneron will lead research and development activities, while Sanofi will oversee global commercialisation. The existing profit-sharing arrangement for Dupixent will remain unchanged. The companies have also resolved their previous litigation related to their collaboration. The expanded alliance continues a partnership that began in 2003. The collaboration has resulted in several approved medicines, with Dupixent becoming a major treatment for conditions associated with type 2 inflammation. More than 1.5 million people are currently receiving Dupixent worldwide. The medicine has been approved in more than 60 countries for a range of conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, bullous pemphigoid and allergic fungal rhinosinusitis, across different age groups. Regeneron and Sanofi are also evaluating dupilumab in additional conditions associated with type 2 inflammation and allergic processes. These include chronic pruritus of unknown origin. These potential uses remain under clinical investigation and have not yet been fully evaluated for safety and efficacy by regulatory authorities.

Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute. By Thomson Reuters Oct 1, 2026 | 1:16 AM By Bhanvi Satija and Mariam Sunny Oct 1 (Reuters) - Sanofi and Regeneron said on Thursday they will develop four new drugs together in a deal worth up to $8 billion and settle prior litigation, moves analysts said signal a reset of their strained partnership and an early win for the French drugmaker's new CEO Belen Garijo. Sanofi will pay $1 billion upfront with an additional $7 billion in potential milestone payments. The companies will equally share development costs and future profits on the four drugs, with Regeneron leading research and Sanofi handling global sales if they are approved. Sanofi shares closed up nearly 1% on Thursday. Shares of Tarrytown, New York-based Regeneron were down 4% in midday trading. "Mutual trust will be the guiding principle in this extended relationship," Garijo said on an investor call, adding that the partnership would include clear roles and accountability for both firms. Garijo, who took over the top role at Sanofi in May and is leading a strategic review of the company, has promised investors faster decision-making. Barclays analysts noted that her predecessor, Paul Hudson, had tried and failed to expand the Regeneron alliance, which produced Sanofi's top-selling medicine, Dupixent, among other drugs. "While the assets are early-stage, the expansion should be viewed positively, as it signals the new CEO's proactive focus on the most important yet addressable uncertainties investors face," said Jefferies analyst Michael Leuchten. The four antibody drugs target the same type 2 inflammation pathways as Dupixent and include REGN20423, currently in early-stage testing for atopic dermatitis, an intensely itchy skin condition also known as eczema. The other three are expected to begin clinical testing in 2027. Regeneron will become eligible for the first $1 billion milestone payment when REGN20423 enters late-stage testing, the drugmaker said. Garijo said the atopic dermatitis market could double in the next five years. "We believe today's deal marks an important step in repairing their relationship and removes a key overhang for both," said BMO Capital Markets analyst Evan Seigerman. However, Markus Manns, a portfolio manager at Union Investment, which holds Sanofi shares, questioned the cost, given the uncertainties of such early-stage assets. "Sanofi certainly paid a full price," he said. MORE M&A REQUIRED Analysts broadly viewed the deal positively but some warned it does not solve Sanofi's fundamental challenge of finding enough pipeline strength to offset Dupixent's patent loss later this decade. Dupixent accounted for 36% of Sanofi's nearly 44 billion euros ($49.39 billion) in 2025 sales. It is approved to treat several conditions, including eczema, asthma, nasal polyps and chronic obstructive pulmonary disease. Sanofi said it was actively working to extend Dupixent's patent exclusivity, but declined to provide details. "This (deal) is the necessary first step toward Sanofi regaining investor trust, but a great deal more is required given a decade of R&D challenges," Guggenheim analysts said. ($1 = 0.8909 euros) (Reporting by Hugo Lhomedet and Matthieu Huchet in Gdansk, Bhanvi Satija in London, and Mariam Sunny in Bengaluru, editing by Milla Nissi-Prussak, Louise Heavens and Bill Berkrot)